Goodman Financial Corp Invests $9.83 Million in Sanofi $SNY

Goodman Financial Corp acquired a new stake in shares of Sanofi (NASDAQ:SNY) during the first quarter, HoldingsChannel.com reports. The institutional investor acquired 204,088 shares of the company’s stock, valued at approximately $9,833,000. Sanofi accounts for approximately 1.7% of Goodman Financial Corp’s investment portfolio, making the stock its 29th biggest position.

Several other institutional investors and hedge funds have also bought and sold shares of SNY. Raymond James Financial Inc. increased its holdings in shares of Sanofi by 81.3% during the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after acquiring an additional 2,635,867 shares in the last quarter. Capital Research Global Investors purchased a new stake in Sanofi in the fourth quarter valued at $79,960,000. Morgan Stanley grew its holdings in Sanofi by 20.4% during the fourth quarter. Morgan Stanley now owns 9,102,196 shares of the company’s stock worth $441,093,000 after acquiring an additional 1,540,271 shares during the period. Manning & Napier Advisors LLC grew its stake in shares of Sanofi by 728,134.8% during the 1st quarter. Manning & Napier Advisors LLC now owns 1,194,305 shares of the company’s stock worth $57,542,000 after purchasing an additional 1,194,141 shares during the period. Finally, Franklin Resources Inc. grew its position in Sanofi by 29.7% during the fourth quarter. Franklin Resources Inc. now owns 5,100,097 shares of the company’s stock valued at $247,151,000 after buying an additional 1,168,339 shares during the period. 14.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. BNP Paribas Exane cut shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research report on Monday, April 20th. Citigroup reissued a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Argus raised shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Finally, Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $49.50.

Sanofi Stock Performance

NASDAQ SNY opened at $44.21 on Friday. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. Sanofi has a fifty-two week low of $40.89 and a fifty-two week high of $52.68. The business has a fifty day moving average of $43.32 and a 200-day moving average of $45.53. The stock has a market cap of $107.18 billion, a price-to-earnings ratio of 12.35, a price-to-earnings-growth ratio of 1.11 and a beta of 0.34.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.